Qiaoying Yuan

Induction of Oxidative stress by Oxidized LDL via Meprinα–Activated Epidermal Growth Factor Receptor in Macrophages

AIMS The aim of this study was to explore meprinα-mediated transactivation of the epidermal growth factor receptor (EGFR) and reactive oxygen species (ROS) production in macrophages. METHODS AND RESULTS Accelerated atherosclerotic lesions were established by administration of a high-fat diet in apolipoprotein E-deficient (apoE(-/-)) mice. Lentiviral overexpression of meprinα in the thoracic aortic artery during plaque formation enhanced intra-plaque macrophage induction of ROS as well as formation of atherosclerotic plaques, whereas AG1478 (specific inhibitor of the EGFR) treatment exerted the opposite effect. A meprinα inhibitor abrogated EGFR activation in mice. In cultured J774a.1 macrophages, oxidized low-density lipoprotein (OxLDL) increased ROS formation and EGFR activation through a ligand [heparin-binding epidermal growth factor-like growth factor (HB-EGF)]-dependent pathway. However, a meprinα inhibitor or specific siRNA inhibited ROS production and EGFR activation. Recombinant mouse meprinα enhanced OxLDL-stimulated production of ROS and induced HB-EGF. Inhibition of p38 mitogen-activated protein kinase by SB203580 decreased OxLDL-stimulated production of ROS. Conversely, inhibition of meprinα or PI3K-Rac1 inhibitors also decreased p38 activity in OxLDL-stimulated macrophages. In addition, inhibition of meprinα reversed OxLDL-stimulated activation of PI3K. CONCLUSION Meprinα promotes OxLDL-induced plaque formation and ROS release by transactivation of the EGFR, followed by activation of the PI3K/Rac1/p38 pathway.

Transendocardial delivery of HGF via microbubbles and ultrasound to treat acute myocardial infarction.

To enhance the safety of transendocardial delivery and the efficacy of intramyocardial angiogenic gene expression, a visible, less invasive, targeted, high-efficiency gene delivery strategy was tested. Progress toward clinical approval of systemic administration of genes and microbubbles (MBs) has been limited. The feasibility of transendocardially delivering MBs as extracellular markers and gene carriers in conjunction with intracardiac ultrasound (US) treatment remains unknown. In a canine acute myocardial infarction (MI) model, a naked plasmid encoding 500 μg human hepatocyte growth factor (HGF) was delivered transendocardially to the myocardium via US/MB (HGF-US/MB), insonation (HGFUS), or alone (HGF alone). Control MI dogs received saline without US/MB (control group). During US/MB, intracardiac insonation was performed for 30 s with a 10-s pause, at 4.3-MHz, 1-W/cm(2), for 60 s at each site. Gene and MB distribution in the myocardium was visualized. Compared to the HGF alone group at 28 days, the HGF-US/MB group had an average 7.1-fold enhancement in gene expression (P < 0.01). Compared to the control group, there were 16% decreases in the ratio of left ventricle (LV) weight/body weight in the HGF-US/MB group and decreases in collagen volume fraction (CVF) of type I (33%) and type III (23%) collagen. Capillary density increased from 22.8 ± 6.3/mm(2) in the control group to 154.3 ± 42.9/mm(2) in the HGF-US/MB group (P < 0.01). This less invasive catheter-based US therapeutic procedure offers observable gene delivery with higher therapeutic efficiency, enhanced angiogenesis, and improved myocardial perfusion and ventricular function following MI.

A transendocardial delivery and intracardiac ultrasound irradiation treatment catheter.

Abstract Objectives: This study introduces the structural design, working principles, performance testing and treatment effects of a newly developed ultrasonic irradiation delivery and treatment catheter system that integrates interventional catheterization technology. Background: Systemic administration method needs a high dose of gene and induces side effect of non-target organ delivery. Direct intramyocardial injection of a low-dose angiogenic gene followed by insonation treatment can enhance gene expression. So, a novel transendocardial gene delivery and intracardiac ultrasound irradiation strategy was tested. Methods: The medical interventional ultrasonic therapeutic apparatus is comprised of an ultrasonic irradiation catheter and a host. The ultrasonic irradiation catheter, which is equipped with an advance-and-retreat convenient miniature syringe needle and a miniature piezoelectric transducer on the tip, was used. Twelve dogs were divided into three groups: (1) EGFP and US (EGFP + US), (2) EGFP alone and (3) control group. In the EGFP + US group, EGFP plasmid DNA (500 µg) was injected and followed by intracardiac insonation. In the EGFP alone group, EGFP plasmid DNA (500 µg) was injected without insonation. In the control group, saline was injected. Results: The catheter can enter the heart through percutaneous intervention to realize intramyocardial injection, directly irradiate cardiac muscular tissues at close range and correctly control the ultrasonic irradiation energy delivered to cardiac muscular tissues. Compared with the EGFP gene group, an average sixfold enhancement in gene expression was achieved in the EGFP EGFP + US group (p < 0.05). Conclusions: The experimental results confirmed that the treatment catheter was safe and reliable, which can realize transendocardial intramyocardial gene injection in the left ventricular chamber, and the ultrasonic parameter can increase gene expression after intracardiac ultrasonic irradiation. The intracardiac ultrasound irradiation treatment catheter may be a useful delivery and therapy tool in the future.

Retraction Note: A novel method of augmenting gene expression and angiogenesis in the normal and ischemic canine myocardium

This study presents a novel method that direct intramyocardial injection of low-dose plasmid DNA and microbubbles combined with insonation could further augment gene expression in normal and ischemic canine myocardium. Plasmids encoding enhanced green fluorescent protein (pEGFP) and hepatocyte growth factor (pHGF) (500 μg) were individually mixed with 0.5 ml of microbubble solution (MB) and injected into the normal or acute ischemic canine myocardium. The dogs in the plasmid + MB/US group underwent insonation (US). Other dogs were randomly divided into three treatment groups: plasmid and insonation, plasmid and MB injection, and plasmid injection only. The EGFP and HGF mRNA expressions were assessed in the myocardium at the injection site and at sites 0.5 and 1 cm remote from the injection site. Compared to plasmid transfer alone, a mean 13.4-fold enhancement of gene expression was achieved in the EGFP + MB/US group at 48 h (p < 0.01). HGF mRNA expression in ischemic zones was markedly elevated after 28 days, with a mean 9.0-fold enhancement in the HGF + MB/US group (p < 0.01). EGFP protein expression was detected in the normal myocardium at 1 cm remote from the injection site in the EGFP + MB/US group. Similarly, HGF protein expression was detected in the ischemic myocardium at 0.5 cm remote from the injection site in the HGF + MB/US group. These findings indicate that the radius of gene expression was partly extended in the two plasmid + MB/US groups. The capillary density increased from 20.9 ± 5.3/mm2 in control myocardial infarction dogs without treatment to 126.7 ± 38.2/mm2 in the HGF + MB/US group (p < 0.01). Taken together, the present data demonstrate that direct intramyocardial injection of an angiogenic gene and microbubbles combined with insonation can augment gene expression and angiogenesis. Consequently, this strategy may be a useful tool for gene therapy of ischemic heart disease.